Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma

Judy AhrarDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Sanjay GuptaDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USACorrespondence[email protected]

Joe EnsorDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Kamran AhrarDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

David C. MadoffDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Michael J. WallaceDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Ravi MurthyDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Alda TamDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Patrick HwuDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Agop Y. BedikianDepartments of Diagnostic Radiology, Biostatistics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

show all

Abstract

We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9%) or disease stabilization (47.2%) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p = .034).

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma

Information for

Open access

Opportunities

Help and information

Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature